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Aims To characterize adverse ventricular remodelling after withdrawing therapy in recovered dilated cardiomyopathy
(DCM).
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Methods
and results
TRED-HF was a randomized controlled trial with a follow-on single-arm cross-over phase that examined the safety
and feasibility of therapy withdrawal in patients with recovered DCM over 6 months. The primary endpoint was
relapse of heart failure defined by (i) a reduction in left ventricular (LV) ejection fraction >10% and to <50%, (ii)
>10% increase in LV end-diastolic volume and to above the normal range, (iii) a twofold rise in N-terminal pro-B-type
natriuretic peptide and to >400 ng/L, or (iv) evidence of heart failure. LV mass, LV and right ventricular (RV) global
longitudinal strain (GLS) and extracellular volume were measured using cardiovascular magnetic resonance at baseline
and follow-up (6 months or relapse) for 48 patients. LV cell and extracellular matrix masses were derived. The effect
of withdrawing therapy, stratified by relapse and genotype, was investigated in the randomized and follow-on phases.
In the randomized comparison, withdrawing therapy led to an increase in mean LV mass [5.4 g/m2; 95% confidence
interval (CI) 1.3–9.5] and cell mass (4.2 g/m2; 95% CI 0.5–8.0) and a reduction in LV (3.5; 95% CI 1.6–5.5) and RV
(2.4; 95% CI 0.1–4.7) GLS. In a non-randomized comparison of all patients (n = 47) who had therapy withdrawn in
either phase, there was an increase in LV mass (6.2 g/m2; 95% CI 3.6–8.9; P = 0.0001), cell mass (4.0 g/m2; 95% CI
1.8–6.2; P = 0.0007) and matrix mass (1.7 g/m2; 95% CI 0.7–2.6; P = 0.001) and a reduction in LV GLS (2.7; 95% CI
1.5–4.0; P = 0.0001). Amongst those who had therapy withdrawn and did not relapse, similar changes were observed
(n = 28; LV mass: 5.1 g/m2, 95% CI 1.5–8.8, P = 0.007; cell mass: 3.7 g/m2, 95% CI 0.3–7.0, P = 0.03; matrix mass:
1.7 g/m2, 95% CI 0.4–3.0, P = 0.02; LV GLS: 1.7, 95% CI 0.1–3.2, P = 0.04). Patients with TTN variants (n =10) who
had therapy withdrawn had a greater increase in LV matrix mass (mean effect of TTN: 2.6 g/m2; 95% CI 0.4–4.8;
P = 0.02).
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Conclusion In TRED-HF, withdrawing therapy caused rapid remodelling, with early tissue and functional changes, even amongst
patients who did not relapse.
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Introduction
Dilated cardiomyopathy (DCM) is characterized by eccentric
hypertrophy associated with an increase in myocyte size and extra-
cellular matrix expansion due to interstitial and focal replacement
fibrosis.1,2 Left ventricular (LV) reverse remodelling is character-
ized by reduction in LV size, regression of hypertrophy and fibrosis
and an improvement in systolic function. It may be observed in
as many as 40–60% of cases and is associated with resolution of
symptoms and an excellent outcome.3,4
Recent work from our group has demonstrated that many
asymptomatic patients with DCM and improved LV function relapse
after withdrawing heart failure therapy.5 This confirms that these
patients have remission of heart failure rather than sustained
recovery or cure.5 Amongst these patients, relapse is characterized
by LV dilatation and deterioration in systolic function.
Knowledge of the features that accompany early adverse remod-
elling should lead to improved understanding of disease pathophys-
iology and may guide the use of treatments that target cellular and
interstitial components of the disease. Previous work has demon-
strated important sex and genotype differences in remodelling
amongst patients with DCM.6,7 Knowledge of disease characteris-
tics that influence the type and degree of remodelling might enable
personalized treatment.2,8
Cardiovascular magnetic resonance (CMR) enables comprehen-
sive characterization of ventricular remodelling. This includes the
assessment of ventricular function and myocardial deformation as
well the quantification of LV mass and its cellular and extracellular
components, using parametric mapping.9
In this study, serial CMR assessment was used to characterize
changes in myocardial tissue composition and myocardial mechan-
ics after withdrawing therapy, with or without relapse, amongst
patients taking part in TRED-HF (Therapy withdrawal in REcovered
DCM-Heart Failure).5
Methods
TRED-HF was an open-label, randomized trial with a follow-on
single-arm cross-over phase examining the safety and feasibility of with-
drawing treatments for heart failure in patients with recovered DCM.
A full description of the methods is provided elsewhere.5 The trial was
registered on ClinicalTrials.gov (NCT02859311).
The study was approved by the National Research Ethics Commit-
tee and authorized by the Medicine and Healthcare Products Regula-
tory Agency. All participants provided written, informed consent. At
inclusion, all participants were asymptomatic and had a diagnosis of
recovered DCM, with a previous LV ejection fraction (LVEF) <40%
that subsequently improved to ≥50%, with normal LV end-diastolic
volume, a N-terminal pro-B-type natriuretic peptide (NT-proBNP)
level <250 ng/L and who were still taking at least one heart failure
therapy [loop diuretic, beta-blocker, angiotensin-converting enzyme
(ACE) inhibitor, angiotensin receptor blocker (ARB) or mineralocor-
ticoid receptor antagonist (MRA)]. Patients were randomized 1:1 to
phased withdrawal of pharmacological heart failure therapy or to con-
tinue therapy, over 6 months. Patients had CMR assessment at baseline,
16 weeks and 6 months.
Therapy was withdrawn in a supervised, step-wise fashion over a



















































































.. clinic or telephone review. Loop diuretics, if prescribed, were with-
drawn first, followed by MRAs, beta-blockers and ACE inhibitors
or ARBs. Those randomized to the control arm continued therapy
and had follow-up visits at 8 weeks, 16 weeks and 6 months. After
6 months, these patients entered a single-arm cross-over phase and
had therapy withdrawn, as described above, between 6–12 months.
They were followed up in the same way as the randomized phase of
the trial after entering the cross-over phase.
The primary endpoint was a relapse of DCM defined by any one
of the following: (i) a reduction in LVEF by >10% and to <50%, or
(ii) an increase in LV end-diastolic volume by >10% and to above the
normal range, or (iii) a twofold rise in NT-proBNP from baseline and
to >400 ng/L, or (iv) clinical evidence of heart failure. Therapy was
re-introduced as soon as any of the primary endpoint criteria were
fulfilled. The management of patients who did not meet the primary
endpoint, but suffered adverse events was determined by the study
team and the participant’s usual physicians.
Cardiovascular magnetic resonance
Cardiovascular magnetic resonance was performed at baseline,
16 weeks and 6 months, in both the randomized and cross-over
phases, using a standardized protocol on a single 3 Tesla scanner
(Skyra, Siemens, Erlangen, Germany). Long- and short-axis cine images
were acquired using breath-hold steady-state free precession images.
Measurement of ventricular volumes and mass was carried out using
CMR Tools (Cardiovascular Imaging Solutions, London, UK) using a
thresholding technique that includes papillary muscles and trabeculae
as part of the LV mass. LV and right ventricular (RV) global longitudinal
strain (GLS) were measured from the horizontal long-axis view by a
single expert operator (X.C.), who was blinded to trial arm and phase,
using feature-tracking software (Medis Suite MR, Medis, Leiden, The
Netherlands).
At baseline and 6 months in the randomized and cross-over
phases, native and post-contrast T1 maps were acquired at basal and
mid-ventricular level in identical short-axis planes, using a breath-hold
5-3-3 modified Look–Locker inversion recovery sequence. Two maps
were acquired in each plane. Post-contrast maps were acquired,
15 min after the administration of gadobutrol (0.1 mmol/kg). A sin-
gle expert operator (V.V.) who was blinded to study arm and phase,
measured global myocardial and blood pool T1 on short-axis slices
using dedicated software (CVI42, Circle Cardiovascular Imaging, Cal-
gary, Alberta, Canada). Endocardial and epicardial borders were con-
toured and partial volume artefact from blood was minimized by using
a 10% automatic offset from each border. The extracellular volume
(ECV) fraction was calculated from the mean myocardial and blood
pool T1 values using a published formula.9 The haematocrit was taken
from blood tests performed immediately before each scan. LV mass
was calculated from the LV volume and specific gravity of myocardium
(1.05 g/mL); LV cell and extracellular matrix mass were derived using
the ECV fraction.
Statistical analysis
Characteristics of patients are presented at randomization.
Variables are presented as mean/standard deviation (SD), or
median/interquartile range if skewed and compared between men and
women and carriers and non-carriers of TTNtv using Mann–Whitney
U test for continuous data and Fisher’s exact test for categorical
data. The effect of withdrawing therapy on LV, cell and matrix mass
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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index and LV and RV GLS was examined by comparing these variables
between randomized groups using a regression model in which the
value at follow-up was the response variable and the treatment indica-
tor and value at baseline were the explanatory variables (i.e. analysis
of covariance). It was estimated that a sample size of at least 28 (14
in each group) would have 80% power to detect a 6 g/m2 increase
in LV mass, with the hypothesis that this would be driven by cellular
rather than interstitial changes in the early phase, assuming a standard
deviation of 6 for interstudy change and an alpha of 0.05.
Since the number of patients was small, we also performed a
non-randomized comparison of these values before and after therapy
was withdrawn in either the randomized (baseline at 0 months) and
cross-over phases (baseline at 6 months). Comparisons were made
using paired t-tests.
Differences in the change in these values were also compared
amongst men and women and amongst carriers and non-carriers of
TTNtv using analysis of covariance.
A P-value of <0.05 was taken as significant throughout. Statistical
analyses were performed using Stata version 15.1 (Stat Corp., College
Station, TX, USA).
Results
Of the 51 patients randomized, two were excluded as echocardio-
graphy was performed in place of CMR due to implanted electronic
cardiac devices. One patient withdrew from the study shortly
after enrolment. Therefore, data from 48 patients were included
(Figure 1). One patient randomized to the control arm did not
cross-over after 6 months, therefore analyses examining patients
who had therapy withdrawn in either phase of the study included
47 patients. Baseline and follow-up parametric mapping data were
not available, due to the sequence being unavailable, for 13 of 48
patients in the randomized phase and 11 of 47 patients who had
therapy withdrawn in either phase of the study.
At enrolment, the mean age of patients was 53 years (SD 12.1)




















































. was idiopathic DCM (n = 33, 68.8%) and 10 (20.8%) patients
were carriers of TTNtv. Mean values for ventricular volumes,
ejection fraction and LV mass were within normal ranges.10,11 The
mean (SD) LVEF, LV GLS, RV ejection fraction and RV GLS at
enrolment were 60.1% (5.7), −21.3 (3.1), 59.2% (5.7) and −27.3
(4.5) respectively, and the mean LVEF at the time of original
diagnosis was 25.7% (9.2). The mean (SD) LV mass, ECV, LV cell
mass and LV matrix mass were 67.7 g/m2 (14.8), 26.0% (2.6),
50.6 g/m2 (12.3) and 17.7 g/m2 (4.0), respectively (Table 1).
Compared to men, women were less likely to have a history
of atrial fibrillation (0% vs. 36.4%; P = 0.009) and late gadolinium
enhancement (13.3% vs. 51.5%; P = 0.02) and had lower systolic
blood pressure [118.3 (12.1) vs. 127.0 (11.1) mmHg; P = 0.06] as
well as lower LV mass [53.6 (7.9) vs. 74.0 (12.7) g/m2; P < 0.0001]
and its components, LV cell mass [38.6 (6.6) vs. 55.9 (10.3) g/m2;
P < 0.0001] and LV matrix mass [13.7 (2.0) vs. 19.4 (3.4) g/m2;
P < 0.0001]. Carriers of TTNtv tended to be younger [46.7 (12.6)
vs. 54.7 (11.0) years; P = 0.29] with lower LV mass [61.1 (9.7)
vs. 69.4 (15.5) g/m2; P = 0.29] compared to non-carriers (online
supplementary Table S1).
Effect of withdrawing therapy
on remodelling
Comparing remodelling variables amongst the randomized groups,
withdrawing therapy led to an increase in LV mass [estimated mean
effect: 5.4 g/m2; 95% confidence interval (CI) 1.3–9.5; P = 0.01]
and LV cell mass (4.2 g/m2; 95% CI 0.5–8.0; P = 0.03) as well as
worsening LV GLS (3.5; 95% CI 1.6–5.5; P = 0.001) and RV GLS
(2.4; 95% 0.1–4.7; P = 0.04) (Table 2 and Figure 2). There was
no change in any of the variables between baseline and follow-up
amongst patients who continued therapy.
In a non-randomized comparison of variables between baseline
and follow-up for patients who had therapy withdrawn in either
Figure 1 Derivation of the study cohort. AF, atrial fibrillation; TTE, transthoracic echocardiography.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Demographics
Age, years 53.0 (12.1) 52.4 (13.0) 53.6 (10.3) 0.88
Men 33 (68.8) 18 (72.0) 15 (65.2) 0.76
Previous cardiovascular history
Time since initial DCM diagnosis, months 60.8 (41.2) 55.7 (41.9) 66.4 (40.8) 0.24
LVEF at initial diagnosis, % 25.7 (9.2) 25.4 (8.6) 26.2 (9.9) 0.66
Absolute improvement in LVEF, % 30.9 (10.0) 31.1 (8.4) 30.7 (11.6) 0.59
Time since LVEF >50%, months 24.7 (22.7) 26.8 (24.5) 26.6 (19.8) 0.77
Previous heart failure admission 31 (64.6) 14 (56.0) 17 (73.9) 0.24
Previous atrial fibrillation 12 (25.0) 4 (16.0) 8 (34.8) 0.19
Previous hypertension 4 (8.3) 3 (12.0) 1 (4.3) 0.61
Diabetes mellitus 1 (2.1) 1 (4.0) 0 (0) 1
Smoker 3 (6.3) 3 (12.0) 0 (0) 0.24
Aetiology
Idiopathic 33 (68.8) 14 (56.0) 19 (82.6) 0.15
Familial 6 (12.5) 4 (16.0) 2 (8.7)
Environmental insult 9 (18.8) 7 (28.0) 2 (8.7)
TTNtv 10 (20.8) 4 (16.0) 6 (26.1) 0.49
Medications at enrolment
ACE inhibitor/ARB 48 (100) 25 (100) 23 (100) N/A
Beta-blocker 42 (87.5) 23 (92.0) 19 (82.6) 0.41
MRA 21 (43.8) 11 (44.0) 10 (43.5) 1
Loop diuretic 6 (12.5) 3 (12.0) 3 (13.0) 1
Clinical characteristics at enrolment
Body surface area, m2 2.0 (0.3) 2.0 (0.3) 2.0 (0.3) 0.75
Heart rate, bpm 67.2 (11.0) 69.8 (10.0) 64.3 (11.5) 0.08
Systolic blood pressure, mmHg 124.2 (12.0) 126.0 (11.3) 122.5 (11.5) 0.32
Diastolic blood pressure, mmHg 73.9 (8.9) 75.2 (7.1) 72.6 (10.6) 0.31
Left bundle branch block 7 (14.6) 4 (16.0) 3 (13.0) 1
NT-proBNP, ng/L 68 (38–129) 68 (37–132) 64 (43–96) 0.93
CMR variables at enrolment
LVEDVi, mL/m2 80.4 (12.5) 81.0 (11.5) 79.8 (13.8) 0.89
LVEF, % 60.1 (5.7) 59.0 (5.1) 61.4 (6.2) 0.43
LV mass index, g/m2 67.7 (14.8) 68.5 (12.1) 66.7 (17.6) 0.54
RVEDVi, mL/m2 77.5 (16.6) 76.6 (16.6) 78.6 (16.9) 0.64
RVEF, % 59.2 (5.7) 58.8 (6.1) 59.6 (5.2) 0.68
LGE, presence 19 (39.6) 10 (40.0) 9 (39.1) 1
Extracellular volume, % 26.0 (2.6) 26.5 (2.8) 25.6 (2.5) 0.38
Cell mass index, g/m2 50.6 (12.3) 51.0 (9.7) 50.3 (14.5) 0.55
Matrix mass index, g/m2 17.7 (4.0) 18.4 (3.8) 17.1 (4.3) 0.4
LV global longitudinal strain, % −21.3 (3.1) −21.0 (3.1) −21.5 (3.2) 0.35
RV global longitudinal strain, % −27.3 (4.5) −27.4 (5.0) −27.3 (4.1) 0.81
Data presented as mean (standard deviation), n (%), or median (IQR).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CMR, cardiovascular magnetic resonance; DCM, dilated cardiomyopathy; GLS, global longitudinal
strain; LGE, late gadolinium enhancement; LV, left ventricular; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid
receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RV, right ventricular; RVEDVi, right ventricular end-diastolic volume index; RVEF, right ventricular
ejection fraction; TTNtv, truncating variant in the gene encoding titin.
the randomized or cross-over phases, there was also an increase
in LV mass (mean change: 6.2 g/m2; 95% CI 3.6–8.9; P = 0.0001),
LV cell mass (4.0 g/m2; 95% CI 1.8–6.2; P = 0.0007) and LV matrix
mass (1.7 g/m2; 95% CI 0.7–2.6; P = 0.001) and a reduction
in LV GLS (2.7; 95% CI 1.5–4.0; P = 0.0001) (Table 3). In a








. therapy withdrawn and who did not meet the trial criteria for
relapse (n = 28), there was an increase in LV mass (mean change:
5.1 g/m2; 95% CI 1.5–8.8; P = 0.007), LV cell mass (3.7 g/m2;
95% CI 0.3–7.0; P = 0.03) and LV matrix mass (1.7 g/m2; 95% CI
0.4–3.0; P = 0.02) and a reduction in LV GLS (1.7; 95% CI 0.1–3.2;
P = 0.04).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 The effect of therapy withdrawal on myocardial remodelling
Mean (SD) in continued
treatment group(n = 25)a
Mean (SD) in treatment
withdrawal group(n = 23)b
Estimated mean effect of
treatment withdrawal (95% CI)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LV mass (g/m2)
Baseline 68.5 (12.1) 66.7 (17.6)
Follow-up 68.5 (12.3) 72.7 (13.1) 5.4 (1.3–9.5) 0.01
LV cell mass (g/m2)
Baseline 51.0 (9.7) 50.3 (14.5)
Follow-up 50.1 (10.8) 53.8 (9.9) 4.2 (0.5–8.0) 0.03
LV matrix mass (g/m2)
Baseline 18.4 (3.8) 17.1 (4.3)
Follow-up 18.4 (3.9) 18.7 (4.1) 1.3 (−0.6 – 3.2) 0.19
LV GLS
Baseline −21.0 (3.1) −21.5 (3.2)
Follow-up −21.0 (3.1) −17.6 (4.1) 3.5 (1.6–5.5) 0.001
RV GLS
Baseline −27.4 (5.0) −27.3 (4.1)
Follow-up −26.4 (4.2) −24.0 (4.0) 2.4 (0.1–4.7) 0.04
Change in variables between baseline and 6 months compared between randomized groups using ANCOVA.
CI, confidence interval; GLS, global longitudinal strain; LV, left ventricular; RV, right ventricular; SD, standard deviation.
an = 8 and bn = 4 patients in the continued treatment arm and withdrawal arm, respectively, had missing values for cell mass and matrix mass.
Figure 2 Scatter plots demonstrating changes in remodelling variables between baseline and follow-up for patients in either treatment arm
of the randomized phase. CI, confidence intervals; GLS, global longitudinal strain; LV, left ventricular; RV, right ventricular.
Differences in remodelling by sex
and genotype
Women had smaller LV mass before therapy was withdrawn com-
pared to men [mean (SD) 53.2 (7.8) vs. 74.0 (13.4) g/m2] and
greater absolute increase in LV mass [9.3 (7.6) vs. 4.8 (9.4) g/m2]









.. variables between sexes, the effect of sex on change in LV mass was
non-significant (−3.7 g/m2; 95% CI −10.2, 2.8; P = 0.26) (Table 4).
The effect of sex on change in other variables was also not signifi-
cant (Table 4).
Similarly, carriers of TTNtv who had therapy withdrawn in either
the randomized or cross-over phases of the study, had greater
increases in LV matrix mass compared to patients without TTNtv
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.. (mean effect of TTNtv: 2.6 g/m2; 95% CI 0.4–4.8; P = 0.02) (Table 4).
The effect of genotype on change in other variables was not
significant (Table 4).
Discussion
This is the first study to investigate the serial changes in tissue
characteristics and cardiac mechanics that accompany early adverse
remodelling in patients with DCM. By harnessing advanced CMR
techniques including parametric mapping and feature-tracking, we
demonstrate that withdrawing pharmacological therapy leads to
a rapid reduction in LV and RV GLS and an increase in overall
LV mass and LV cell mass. Due to the relatively small number of
patients, a non-randomized comparison of baseline and follow-up
values amongst all patients who had therapy withdrawn was also
performed. This suggested there was also an increase in LV extra-
cellular matrix mass after therapy was withdrawn. The absence of
a change in remodelling variables over follow-up amongst patients
who continued therapy supports the validity of the findings of the
non-randomized analyses.
These results are important for several reasons. They emphasize
that early adverse remodelling is associated with diminished longi-
tudinal deformation of both the left and right ventricle. This is in
keeping with previous studies which have suggested that DCM is
a global myocardial process that involves both ventricles.12,13 The
development of changes in RV function within 8 weeks of complet-
ing withdrawal of therapy, before the development of symptoms
or elevated plasma concentrations of natriuretic peptides, sup-
ports the notion of intrinsic RV disease, rather than simply remod-
elling related to increasing afterload. Equally, we also recognize the
absence of evidence supporting a beneficial effect of heart failure
therapy on intrinsic RV disease.
Myocardial relapse occurred rapidly amongst patients in the
TRED-HF trial. One might have expected that short-term adverse
remodelling would be driven by cellular changes such as abnormal
calcium handling, energetic dysfunction or sarcomeric dysfunction.
Indeed, a marked increase in LV cell mass was observed after with-
drawing therapy in both the randomized and non-randomized com-
parisons, reflecting myocyte hypertrophy, a pathological hallmark
of DCM.1 Non-randomized comparisons, however, also demon-
strated an increase in LV extracellular matrix mass between base-
line and follow-up after withdrawing therapy. Although this was not
borne out in the randomized comparison, possibly due to small
patient numbers, this suggests that there might also be rapid extra-
cellular matrix remodelling following therapy withdrawal. Whether
this is rapid accumulation of interstitial fibrosis or secondary to
interstitial oedema is unclear but deserves further consideration
and investigation.
Patients who had therapy withdrawn and did not meet the
primary relapse endpoint also had an increase in LV cell mass
and matrix mass and a reduction in GLS. This is in keeping with
the reduction in LVEF reported amongst this group of patients
in the primary analysis5 and confirms evidence of early adverse
remodelling even amongst patients who did not meet the trial
criteria for relapse. This supports the concept that a greater
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 The effect of sex and genotype on myocardial remodelling amongst patients who had therapy withdrawn in
the randomized or cross-over phases
Men vs. women (n = 47)a
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Men (n = 32) Women (n = 15) Estimated mean effect
of male sex (95% CI)
P-value*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean (SD) Mean (SD)
change
Mean (SD) Mean (SD)
change
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LV mass (g/m2)
Baseline 74.0 (13.4) 4.8 (9.4) 53.2 (7.8) 9.3 (7.6) −3.7 (−10.2, 2.8) 0.26
Follow-up 78.9 (10.9) 62.5 (9.4)
LV cell mass (g/m2)a
Baseline 55.7 (10.4) 2.4 (6.5) 38.6 (6.9) 7.6 (5.0) −0.4 (−5.6, 4.7) 0.87
Follow-up 58.1 (8.6) 46.2 (7.3)
LV matrix mass (g/m2)a
Baseline 19.1 (3.7) 1.2 (2.6) 14.2 (2.2) 2.7 (3.3) 0.7 (−1.8, 3.3) 0.56
Follow-up 20.3 (4.0) 16.9 (4.0)
LV GLS
Baseline −20.8 (3.0) 2.4 (4.1) −21.9 (3.5) 3.4 (4.7) 0.6 (−1.6, 2.8) 0.61
Follow-up −18.6 (3.3) −18.2 (3.9)
RV GLS
Baseline −26.2 (4.0) 0.6 (7.0) −27.9 (4.3) 1.2 (4.5) −0.9 (−4.3, 2.4) 0.57
Follow-up −25.6 (5.0) −26.8 (5.3)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-TTNtv vs. TTNtv (n = 47)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-TTNtv (n = 37) TTNtv (n = 10) Estimated mean effect
of TTNtv (95% CI)
P-value*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean (SD) Mean (SD)
change
Mean (SD) Mean (SD)
change
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LV mass (g/m2)
Baseline 69.0 (15.8) 5.1 (9.3) 62.1 (11.5) 10.8 (7.0) 4.0 (−2.0, 9.9) 0.18
Follow-up 74.1 (13.3) 72.8 (11.1)
LV cell mass (g/m2)a
Baseline 52.2 (12.7) 3.2 (6.5) 44.5 (9.0) 6.9 (5.8) 1.4 (−3.1, 5.9) 0.53
Follow-up 55.4 (10.2) 51.4 (7.9)
LV matrix mass (g/m2)a
Baseline 18.0 (4.0) 1.0 (2.7) 16.3 (3.9) 3.9 (2.5) 2.6 (0.4, 4.8) 0.02
Follow-up 19.0 (4.3) 20.2 (4.3)
LV GLS
Baseline −21.7 (3.2) 3.2 (4.0) −19.4 (2.0) 1.1 (5.0) −0.3 (−2.9, 2.3) 0.82
Follow-up −18.5 (3.5) −18.4 (3.3)
RV GLS
Baseline −27.1 (4.4) 0.9 (6.4) −25.6 (3.1) 0.3 (6.1) 0.7 (−3.1, 4.4) 0.71
Follow-up −26.2 (5.1) −25.3 (5.1)
Effect of sex and genotype on change in variables examined using ANCOVA.
CI, confidence interval; GLS, global longitudinal strain; LV, left ventricular; RV, right ventricular; SD, standard deviation.
aSeven male and four female patients had missing values for cell mass and matrix mass.
*P-value calculated using ANCOVA.
proportion of patients would have relapsed if therapy had been
withdrawn for a greater length of time. It also demonstrates the
importance of considering adverse remodelling and relapse as being
on a continuous spectrum rather than an all-or-nothing binary
phenomenon.
Previous work has demonstrated important differences between
men and women with DCM as well as carriers and non-carriers











. total LV, LV cell and LV matrix mass compared to men. After with-
drawing therapy, women had a larger absolute increase in LV mass,
although after adjustment for differences at baseline, the effect of
sex on LV mass was non-significant. The explanation for this is
unclear. It is well established that women are more likely to have
reverse remodelling in response to treatment compared to men.15
It is possible that women have more complete reverse remodelling
compared to men and that following therapy withdrawal, a greater
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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deterioration. Further investigation of sex differences in remod-
elling and the effects of specific therapies are required.
Consistent with previous work,7 carriers of TTNtv tended to
have lower LV mass and cell mass index at baseline.14 Interestingly,
they also had greater expansion of extracellular matrix mass
during therapy withdrawal. Verdonschot and colleagues previously
demonstrated that patients with DCM and TTNtv had greater
interstitial fibrosis compared to genotype negative patients with
DCM.7 Our data support the concept that TTNtv may lead to a
more fibrotic phenotype. Sarcomeric variants have been associ-
ated with up-regulation of genes involved in extracellular matrix
expansion in models of hypertrophic cardiomyopathy.16,17 Other
studies have confirmed that interstitial expansion is an early
feature of disease.16,17 Whether patients with TTNtv may be more
likely to benefit from targeted anti-fibrotic agents deserves further
attention.2
Limitations
The small number of patients in this sub-study and the incom-
plete data on parametric mapping data are important limitations
and should be borne in mind when interpreting the results. Correc-
tion for multiple testing was not performed due to the exploratory
nature of the analysis. The analyses investigating differences in
remodelling based on sex and genotype should be viewed as
hypothesis-generating and require validation in larger studies, con-
sidering the small numbers of patients in these sub-analyses. Never-
theless, these results are consistent with previous data and suggest
that important differences exist within these sub-groups. It should
also be recognized that changes in LV geometry can affect measures
of systolic function, including ejection fraction and strain. Previous
data have confirmed that GLS is confounded to a lesser degree than
ejection fraction by such changes.18
Conclusions
In TRED-HF, withdrawing therapy for heart failure led to a deteri-
oration in measures of LV and RV systolic function and LV hyper-
trophy due to an increase in both LV cell and extracellular matrix
mass within 6 months. This suggests that early adverse remodelling
is a biventricular process with both cellular and interstitial changes.
Such changes were observed amongst patients who had therapy
withdrawn even if they did not meet the trial criteria for relapse,
suggesting that more patients would have relapsed if therapy had
been withdrawn for longer. Sex- and genotype-specific differences
in remodelling may exist; greater understanding of these may enable
more personalized therapy.
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